|
US3024257A
(en)
|
1961-04-10 |
1962-03-06 |
Frosst & Co Charles E |
Stable preparations of alkali metal salts of estrone sulfate
|
|
FR2340735A1
(fr)
|
1976-02-11 |
1977-09-09 |
Roussel Uclaf |
Nouveaux derives de l'acide 3-quinoleine carboxylique, leur procede de preparation et leur application comme medicament
|
|
IE52670B1
(en)
|
1981-03-03 |
1988-01-20 |
Leo Ab |
Heterocyclic carboxamides,compositions containing such compounds,and processes for their preparation
|
|
DE3437232A1
(de)
|
1984-10-10 |
1986-04-17 |
Mack Chem Pharm |
Stabilisierte injektionsloesungen von piroxicam
|
|
US4782155A
(en)
|
1986-03-19 |
1988-11-01 |
Banyu Pharmaceutical Co., Ltd. |
Cephalosporin derivatives, processes for their preparation and antibacterial agents
|
|
SE8902076D0
(sv)
|
1989-06-09 |
1989-06-09 |
Pharmacia Ab |
Derivatives of quinoline-3-carboxanilide
|
|
HUT60458A
(en)
|
1991-02-01 |
1992-09-28 |
Sandoz Ag |
Process for producing benzyloxyphenyl derivatives and pharmaceutical compositions comprising same
|
|
US5139878A
(en)
|
1991-08-12 |
1992-08-18 |
Allied-Signal Inc. |
Multilayer film constructions
|
|
US5540934A
(en)
|
1994-06-22 |
1996-07-30 |
Touitou; Elka |
Compositions for applying active substances to or through the skin
|
|
CH687615A5
(de)
|
1994-09-07 |
1997-01-15 |
R W Johnson Pharmaceutical Res |
Tropen-Verpackung.
|
|
US5912349A
(en)
|
1997-01-31 |
1999-06-15 |
Pharmacia & Upjohn Company |
Process for the preparation of roquinimex
|
|
US20030124187A1
(en)
|
1997-02-14 |
2003-07-03 |
Smithkline Beecham Laboratoires Pharmaceutiques, |
Pharmaceutical formulations comprising amoxycillin and clavulanate
|
|
US6077851A
(en)
*
|
1998-04-27 |
2000-06-20 |
Active Biotech Ab |
Quinoline derivatives
|
|
SE9801474D0
(sv)
|
1998-04-27 |
1998-04-27 |
Active Biotech Ab |
Quinoline Derivatives
|
|
SE9802550D0
(sv)
|
1998-07-15 |
1998-07-15 |
Active Biotech Ab |
Quinoline derivatives
|
|
SE9802549D0
(sv)
|
1998-07-15 |
1998-07-15 |
Active Biotech Ab |
Quinoline derivatives
|
|
US6133285A
(en)
|
1998-07-15 |
2000-10-17 |
Active Biotech Ab |
Quinoline derivatives
|
|
US6121287A
(en)
|
1998-07-15 |
2000-09-19 |
Active Biotech Ab |
Quinoline derivatives
|
|
SI1187601T1
(sl)
|
1999-06-07 |
2005-12-31 |
Altana Pharma Ag |
Novi pripravek in dajalna oblika, ki obsega kislinsko labilen inhibitor protonske crpalke
|
|
CN100390148C
(zh)
|
1999-10-25 |
2008-05-28 |
活跃生物技术有限公司 |
用于治疗恶性肿瘤的药物
|
|
SE0002320D0
(sv)
|
1999-10-25 |
2000-06-21 |
Active Biotech Ab |
Malignant tumors
|
|
JP2002031610A
(ja)
|
2000-07-14 |
2002-01-31 |
Ajinomoto Co Inc |
生体分子複合体の界面残基を同定する方法
|
|
US6307050B1
(en)
|
2000-08-29 |
2001-10-23 |
R. T. Alamo Venture I Llc |
Method of synthesizing flosequinan from 4-fluoroanthranilic acid
|
|
US6802422B2
(en)
|
2000-12-12 |
2004-10-12 |
Multi-Comp, Inc. |
Sealed blister assembly
|
|
US6706733B2
(en)
|
2001-05-08 |
2004-03-16 |
Dainippon Ink And Chemicals, Inc. |
Quinolinone derivative formulation and its production method
|
|
US20030119826A1
(en)
|
2001-09-24 |
2003-06-26 |
Pharmacia Corporation |
Neuroprotective treatment methods using selective iNOS inhibitors
|
|
US7560557B2
(en)
|
2002-06-12 |
2009-07-14 |
Active Biotech Ag |
Process for the manufacture of quinoline derivatives
|
|
SE0201778D0
(sv)
|
2002-06-12 |
2002-06-12 |
Active Biotech Ab |
Process for the manufacture of quinoline derivatives
|
|
US6875869B2
(en)
|
2002-06-12 |
2005-04-05 |
Active Biotech Ab |
Process for the manufacture of quinoline derivatives
|
|
ITMI20021726A1
(it)
|
2002-08-01 |
2004-02-02 |
Zambon Spa |
Macrolidi ad attivita' antiinfiammatoria.
|
|
US7820145B2
(en)
|
2003-08-04 |
2010-10-26 |
Foamix Ltd. |
Oleaginous pharmaceutical and cosmetic foam
|
|
US7790197B2
(en)
|
2003-06-09 |
2010-09-07 |
Warner-Lambert Company Llc |
Pharmaceutical compositions of atorvastatin
|
|
US20050271717A1
(en)
|
2003-06-12 |
2005-12-08 |
Alfred Berchielli |
Pharmaceutical compositions of atorvastatin
|
|
US20040253305A1
(en)
|
2003-06-12 |
2004-12-16 |
Luner Paul E. |
Pharmaceutical compositions of atorvastatin
|
|
AU2003300692A1
(en)
|
2003-10-30 |
2005-05-19 |
Lupin Ltd. |
Stable formulations of ace inhibitors and methods for preparation thereof
|
|
SE0400235D0
(sv)
|
2004-02-06 |
2004-02-06 |
Active Biotech Ab |
New composition containing quinoline compounds
|
|
US8314124B2
(en)
|
2004-02-06 |
2012-11-20 |
Active Biotech Ab |
Crystalline salts of quinoline compounds and methods for preparing them
|
|
PL1902034T3
(pl)
|
2005-06-02 |
2011-09-30 |
Glenmark Pharmaceuticals Sa |
Nowe ligandy receptorów kanabinoidowych, kompozycja farmaceutyczna je zawierająca oraz proces ich wytwarzania
|
|
KR101440982B1
(ko)
|
2005-10-19 |
2014-09-17 |
테바 파마슈티컬 인더스트리즈 리미티드 |
라퀴니모드 나트륨의 결정 및 이의 제조방법
|
|
BRPI0708902A2
(pt)
|
2006-03-16 |
2011-06-14 |
Genentech Inc |
mÉtodos de tratar lupus usando anticorpos cd4
|
|
US7989473B2
(en)
*
|
2006-06-12 |
2011-08-02 |
Teva Pharmaceutical Industries, Ltd. |
Stable laquinimod preparations
|
|
SI2056807T1
(sl)
|
2006-08-17 |
2012-12-31 |
University Of Chicago |
Zdravljenje vnetnih bolezni
|
|
EP2214657A1
(en)
|
2007-10-23 |
2010-08-11 |
UCB Pharma GmbH |
Compounds for treating demyelination conditions
|
|
US8178127B2
(en)
*
|
2007-12-20 |
2012-05-15 |
Teva Pharmaceuticals Industries, Ltd. |
Stable laquinimod preparations
|
|
US8354428B2
(en)
|
2008-07-01 |
2013-01-15 |
Actavis Group Ptc Ehf |
Solid state forms of laquinimod and its sodium salt
|
|
JP2012502038A
(ja)
|
2008-09-03 |
2012-01-26 |
テバ ファーマシューティカル インダストリーズ リミティド |
免疫機能の２−オキソ−１，２−ジヒドロ−キノリンモジュレーター
|
|
TW201014605A
(en)
|
2008-09-16 |
2010-04-16 |
Genentech Inc |
Methods for treating progressive multiple sclerosis
|
|
UY32427A
(es)
|
2009-02-13 |
2010-09-30 |
Boheringer Ingelheim Internat Gmbh |
Composicion farmaceutica, forma farmaceutica, procedimiento para su preparacion, metodos de tratamiento y usos de la misma
|
|
US20100260755A1
(en)
|
2009-04-09 |
2010-10-14 |
Medicinova, Inc. |
Ibudilast and immunomodulators combination
|
|
DK2442651T3
(en)
|
2009-06-19 |
2015-09-21 |
Teva Pharma |
Treatment of multiple sclerosis with laquinimod
|
|
MX2012001333A
(es)
|
2009-07-30 |
2012-06-01 |
Teva Pharma |
Tratamiento de la enfermedad de crohn con la laquinimod.
|
|
PT2467372T
(pt)
|
2009-08-10 |
2016-08-23 |
Teva Pharma |
Tratamento de distúrbios relacionados com bdnf usando laquinimod
|
|
US20130035390A1
(en)
*
|
2010-01-13 |
2013-02-07 |
Ramot At Tel-Aviv University Ltd. |
Treatment of multiple sclerosis
|
|
AU2011223702B2
(en)
|
2010-03-03 |
2016-07-14 |
Teva Pharmaceutical Industries Ltd. |
Treatment of lupus arthritis using laquinimod
|
|
SG183513A1
(en)
|
2010-03-03 |
2012-09-27 |
Teva Pharma |
Treatment of rheumatoid arthritis with a combination of laquinimod and methotrexate
|
|
EP2590653A4
(en)
|
2010-07-09 |
2014-01-01 |
Teva Pharma |
5-CHLORO-4-HYDROXY-1-METHYL-2-OXO-N-PHENYL-1,2-DIHYDROCHINOLINE-3-CARBOXAMIDE, SALT THEREOF AND APPLICATIONS THEREOF
|
|
CN104610144A
(zh)
|
2010-07-09 |
2015-05-13 |
泰华制药工业有限公司 |
氘化的n-乙基-n-苯基-1,2-二氢-4-羟基-5-氯-1-甲基-2-氧代喹啉-3-甲酰胺、其盐和用途
|
|
EP2463289A1
(en)
|
2010-11-26 |
2012-06-13 |
Almirall, S.A. |
Imidazo[1,2-b]pyridazine derivatives as JAK inhibitors
|
|
SG10201509831XA
(en)
|
2010-12-07 |
2015-12-30 |
Teva Pharma |
Use of laquinimod for reducing fatigue, improving functional status, and improving quality of life in multiple sclerosis patients
|
|
EP2537517A1
(en)
|
2011-06-22 |
2012-12-26 |
Active Biotech AB |
Deuterium-enriched 4-hydroxy-5-methoxy-n,1-dimethyl-2-oxo-n-[(4-trifluoro-methyl)phenyl]-1,2-dihydroquinoline-3-carboxamide
|
|
IN2014MN00333A
(OSRAM)
|
2011-07-28 |
2015-09-25 |
Teva Pharma |
|
|
JP2014521659A
(ja)
|
2011-07-28 |
2014-08-28 |
テバ ファーマシューティカル インダストリーズ リミティド |
ラキニモドおよびインターフェロンβを組み合わせた多発性硬化症の治療
|
|
EP2766020A4
(en)
|
2011-10-12 |
2015-04-01 |
Teva Pharma |
TREATMENT OF MULTIPLE SCLEROSIS BY COMBINING LAQUINIMOD AND FINGOLIMOD
|
|
JP2015505564A
(ja)
|
2012-02-03 |
2015-02-23 |
テバ ファーマシューティカル インダストリーズ リミティド |
第一選択の抗ＴＮＥα療法に失敗したクローン病患者を治療するためのラキニモドの使用
|
|
JP6215238B2
(ja)
|
2012-02-16 |
2017-10-18 |
テバ ファーマシューティカル インダストリーズ リミティド |
Ｎ−エチル−ｎ−フェニル−１，２−ジヒドロ−４，５−ジ−ヒドロキシ−１−メチル−２−オキソ−３−キノリンカルボキサミド、その製剤、および使用
|
|
US20130259856A1
(en)
|
2012-03-27 |
2013-10-03 |
Teva Pharmaceutical Industries, Ltd. |
Treatment of multiple sclerosis with combination of laquinimod and dimethyl fumarate
|
|
AR090885A1
(es)
|
2012-05-02 |
2014-12-10 |
Teva Pharma |
Uso de laquinimod en alta dosis para el tratamiento de la esclerosis multiple
|
|
TW201350467A
(zh)
|
2012-05-08 |
2013-12-16 |
Teva Pharma |
Ｎ－乙基－４－羥基－１－甲基－５－（甲基（２，３，４，５，６－五羥基己基）胺基）－２－側氧－ｎ－苯基－１，２－二氫喹啉－３－甲醯胺
|
|
US20130345257A1
(en)
|
2012-06-26 |
2013-12-26 |
The Regents Of The University Of California |
Composition for lupus nephritis and methods of making and using the same
|
|
AR091706A1
(es)
|
2012-07-11 |
2015-02-25 |
Teva Pharma |
Formulaciones de laquinimod sin agentes alcalinizantes
|
|
UY34896A
(es)
|
2012-07-12 |
2014-02-28 |
Teva Pharma |
Tratamiento de la esclerosis múltiple con una combinación de laquinimod y fampridina
|
|
TW201410243A
(zh)
|
2012-08-13 |
2014-03-16 |
Teva Pharma |
用於治療大麻素受體型１（ｃｂ１）媒介之疾病之拉喹莫德（ｌａｑｕｉｎｉｍｏｄ）
|
|
TW201410244A
(zh)
|
2012-08-13 |
2014-03-16 |
Teva Pharma |
用於治療ｇａｂａ媒介之疾病之拉喹莫德（ｌａｑｕｉｎｉｍｏｄ）
|